Committees : NW Surrey Medicines Optimisation Group
You are here : Home > Committees : NW Surrey Medicines Optimisation Group
Committee Types
Please select an organisation name from the list below to view associated profiles and decisions.
Committee
- ASPH DTC
- East Surrey CCG Medicines Programme Board
- East Surrey MOG
- Epsom St Helier NDAIG
- ESCCG sub-committee of North Place Alliance Clinical Strategy Committee (formerly Clinical Executive
- Guildford and Waverley MOG
- Medicines Optimisation Operational Group (MOOG)
- Not Set
- NW Surrey Medicines Optimisation Group
- Primary Care Medicines Optimisation Clinical reference Group (PCMOCRG)
- RSFT DTC
- SASH DTG
- Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
- Surrey Downs CCG Prescribing Leads Meeting
- Surrey Downs MOG
- Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
- Surrey Heartlands Medicines Optimisation Board (MOB)
- Surrey Heartlands Medicines Safety Committee (MSC)
- Surrey Medicines Commissioners Group
Trust
Profiles (0)
No records returned.
Committee Recommendations (9)
North West Surrey / ASPH local recommendation:
Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.
See the "NWS Enoxaparin brand switch" document for details
North West Surrey / ASPH local recommendation:
Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.
See the "NWS Enoxaparin brand switch" document for details
North West Surrey / ASPH local recommendation:
Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.
See the "NWS Enoxaparin brand switch" document for details
North West Surrey / ASPH local recommendation:
Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.
See the "NWS Enoxaparin brand switch" document for details
North West Surrey / ASPH local recommendation:
Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.
See the "NWS Enoxaparin brand switch" document for details
The Surrey Heartlands preferred brands of oxycodone are:
Longtec (oxycodone modified release)
Shortec (oxycodone immediate release)
The North West Surrey MOG, in agreement with ASPH, have aligned their preferred brands of oxycodone with the rest of Surrey Heartlands and now recommend Longtec / Shortec.
There is no requirement so switch patients who are currently receiving other brands.
o ACE inhibitors and angiotensin II receptor antagonists
o Digoxin
o NSAIDs (including COX IIs)
o Diuretics